

Edgar Filing: ZONAGEN INC - Form 8-K

ZONAGEN INC
Form 8-K
March 28, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): MARCH 27, 2003

ZONAGEN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)

0-21198
(COMMISSION FILE NUMBER)

76-02
(I.R.S. EMPLOYER I

2408 TIMBERLOCH PLACE, SUITE B-4
THE WOODLANDS, TEXAS 77380
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)

(281) 719-3400
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)

ITEM 5. OTHER EVENTS

On March 27, 2003, Zonagen, Inc. (the "Company") announced in a press release that it had terminated the merger agreement dated as of October 30, 2002 between Zonagen, Lavipharm Corp. and certain of Lavipharm Corp.'s stockholders, effective immediately. The merger agreement had provided that if the merger had not been completed by February 28, 2003, either party could elect to terminate the merger agreement, in its sole discretion.

A copy of the Company's press release announcing the termination of the Merger Agreement is attached hereto as Exhibit 99.1. The press release is incorporated by reference into this Item 5 and the foregoing description of press release is qualified in its entirety by reference to all of the attached exhibits.

ITEM 7. EXHIBITS

Edgar Filing: ZONAGEN INC - Form 8-K

Exhibit 99.1 -- Press Release dated March 27, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZONAGEN, INC.

Date: March 28, 2003.

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.
Vice President, Business Development
and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number -----	Description -----
99.1	Press Release dated March 27, 2003.